Department of Pesticide Regulation

Mary-Ann Warmerdam
Director

Arnold Schwarzenegger
Governor

November 18, 2005

TO: Pesticide Registration and Evaluation Committee

SUBJECT: PRIORITIZATION AND STATUS OF ACTIVE INGREDIENTS FOR RISK CHARACTERIZATION: REPORT # 47

The Birth Defect Prevention Act of 1984 (SB 950) requires the California Department of Pesticide Regulation (DPR) to review the toxicology data for all active ingredients currently registered in California.

As part of this review, the active ingredients listed on the attached list were identified as having potential adverse health effects in studies of sufficient quality to permit risk characterization. As a result, these active ingredients will enter the risk characterization process. During this process, DPR staff will identify the seriousness of the adverse effect, determine the expected levels of human exposure, assess the resulting risk to human health, and, if necessary, explore possible mitigation measures.

The results of this risk characterization process will help DPR staff determine if any registration action is warranted A registration action is not the automatic result for every active ingredient entering the risk characterization process. In addition, as data gaps are filled, other adverse effects might be identified, necessitating another risk characterization. Finally, the risk characterization process should be viewed as a comprehensive evaluation requiring, in some cases, a considerable amount of time. Therefore, it is not possible to predict how long it will take to systematically complete the risk characterization process for each priority category.

When the risk characterization process has been completed, the active ingredient will be removed from this list. The risk characterization document is forwarded to the Assistant Director for approval. Any subsequent risk management activities will be conducted under a separate DPR process.

Attached is a list of active ingredients and the type of corresponding study in which the potential adverse health effects were noted. The active ingredients have been prioritized into High, Moderate, and Low categories. The prioritization of the active ingredients is a subjective process based upon the nature of potential adverse effect, the number of potential adverse effects, the number of species affected, the no observable effect level (NOEL), potential human exposure,

use patterns, quantity used, EPA evaluations and actions, etc. In addition, the status of the active ingredients in risk characterization under Senate Bill 950 (Birth Defects Prevention Act), Assembly Bill (AB) 1807 (Toxic Air Contaminant Act), AB 2161 (Food Safety Act), Proposition 65, and new registration submissions are provided in this report.

Questions about the information contained in this report can be directed to Joyce Gee, Senior Toxicologist in the Medical Toxicology Branch, by telephone at (916) 324-3465, or by e-mail at <jgee@cdpr.ca.gov>.

Sincerely,

Gary Patterson, Ph.D., Chief
Medical Toxicology Branch
(916) 324-3466

Attachment

cc: Joyce Gee

RISK ASSESSMENT PRIORITIZATION LIST
Report # 47
November 18, 2005

The following is a list of the active ingredients that will undergo or are undergoing a risk assessment. The active ingredients have been prioritized into High, Moderate and Low categories. Also listed is the type of toxicity study in which the possible adverse effect(s) was noted.

	Active Ingredient	Studies Indicating Possible Adverse Effects
	High Priority	
1.	Acephate	Genotoxicity study, oncogenicity study, chronic toxicity study, low NOEL
2.	Acrolein	Genotoxicity study, chronic toxicity study, oncogenicity study, reproduction study
3.	Aldicarb	Low NOEL
4.	Arsenic, inorganic	Oncogenicity study (epidemiology), neurotoxicity (epidemiology), genotoxicity study, teratology study
5.	Azafenidin	Chronic toxicity study, oncogenicity study, teratology study, reproduction study
6.	Bromoxynil	Genotoxicity study, oncogenicity study, teratology study
7.	Captan	Genotoxicity study, oncogenicity study
8.	Carbaryl	Genotoxicity study, oncogenicity study
9.	Carbofuran	Reproduction study, chronic study, genotoxicity study
10.	Chloropicrin	Genotoxicity study, teratology study
11.	Chlorothalonil	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
12.	Chlorpyrifos	Genotoxicity study, reproduction study

13.	Creosote	Oncogenicity study, teratology study
14.	Cyfluthrin	Teratology study, reproduction study
15.	Cyhalothrin	Chronic toxicity study, oncogenicity study
16.	Daminozide	Oncogenicity study
17.	Dazomet	Chronic toxicity study, teratology study, genotoxicity study
18.	Diazinon	Genotoxicity study, reproduction study
19.	Dicamba	Neurotoxicity study, chronic toxicity study, oncogenicity study
20.	Dichlobenil	Combined oncogenicity/chronic toxicity study
21.	1,3-dichloropropene (Telone)	Systemic toxicity/short term exposure
22.	Dicofol	Oncogenicity study, low NOEL, reproduction study
23.	Dimethoate	Genotoxicity study, low NOEL
24.	2,4-D	Combined oncogenicity/chronic toxicity study, reproduction study, genotoxicity study
25.	Ethylene thiourea (ETU)	Genotoxicity study, chronic toxicity study, combined oncogenicity/chronic toxicity study
26.	Emamectin	Neurotoxicity in subchronic and chronic studies, reproduction study
27.	Endosulfan	Low NOEL, chronic toxicity study
28.	Ethylene oxide	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
29.	Famoxadone	Chronic toxicity study; genotoxicity study
30.	Fenamiphos	Genotoxicity study, low NOEL

31.	Febuconazole	Chronic toxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, reproduction study, teratology study
32.	Fenvalerate/Esfenvalerate	Neurotoxicity
33.	Fipronil	Chronic toxicity study, combined chronic toxicity/oncogenicity study
34.	*Flonicamid**	Oncogenicity
35.	Flumioxazin	Chronic toxicity study, reproduction study, teratology study
36.	Glufosinate ammonium	Chronic toxicity study, teratology study
37.	Glutaraldehyde	Genotoxicity study, subchronic toxicity study, combined toxicity study
38.	Imazalil	Teratology study
39.	Indoxacarb	Subchronic toxicity studies, combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study, neurotoxicity study
40.	Iprodione	Genotoxicity study, chronic toxicity studies, oncogenicity study
41.	Linuron	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study, reproduction study
42.	Mancozeb	Genotoxicity study, chronic toxicity study (also see ETU)
43.	Methamidophos	Genotoxicity study, low NOEL
44.	Methiocarb	Teratology study
45.	Methyl parathion	Reproduction study, teratology study, genotoxicity study, chronic toxicity study
46.	N-octylbicycloheptene dicarbomixide (MGK-264)	Oncogenicity study

47.	Milbemectin	Reproduction study, neurotoxicity study, subchronic toxicity study
48.	*Novaluron**	Chronic toxicity
49.	Orthophenylphenol	Genotoxicity study, oncogenicity study, teratology study
50.	Oxadiazon	Chronic toxicity study, oncogenicity study, genotoxicity study, teratology study
51.	Oxydemeton-methyl	Reproduction study, genotoxicity study
52.	Paradichlorobenzene	Oncogenicity study, reproduction study, genotoxicity study
53.	Paraquat	Genotoxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, chronic toxicity study
54.	PCNB	Genotoxicity study, oncogenicity studies
55.	Profenofos	Low NOEL, chronic toxicity study
56.	Propanil	Combined oncogenicity/chronic toxicity study, chronic toxicity study, oncogenicity study
57.	Propargite	Reproduction study, genotoxicity study, combined oncogenicity/chronic toxicity study
58.	Propylene oxide	Genotoxicity study, oncogenicity study
59.	Propyzamide	Oncogenicity study
60.	Pyraclostrobin	Subchronic toxicity study, low NOEL's in teratology , chronic and reproduction studies
61.	*Sodium tertathiocarbonate (CS_2)*	Multiple toxicity studies
62.	*Spiromesifin**	Low NOELs
63.	Tebuconazole	Teratology study

64.	*Thiacloprid**	Oncogenicity, reproductive toxicity
65.	Thiazopyr	Subchronic toxicity study, combined oncogenicity /chronic toxicity study
66.	Thiophanate-methyl	Oncogenicity studies, chronic toxicity studies
67.	Tralkoxydim	Chronic toxicity study, combined toxicity study, teratology study
68.	Triadimefon	Teratology study, oncogenicity study, reproduction study, chronic toxicity study
69.	Triallate	Oncogenicity study, chronic toxicity study, genotoxicity study
70.	Tributyltin benzoate	Developmental toxicity study, oncogenicity study
71.	Trifloxysulfuron-sodium	Neurotoxicity study
72.	Vinclozolin	Chronic toxicity study, teratology study, genotoxicity study, reproduction study
73.	Ziram	Oncogenicity study, reproduction study, genotoxicity study

Moderate Priority

1.	Acequinocyl	Chronic toxicity study, reproduction study
2.	Acetamiprid	Subchronic and chronic toxicity studies
3.	Acifluorfen	Genotoxicity study
4.	Acibenzolar-s-methyl	Combined chronic toxicity/oncogenicity study, teratology study, genotoxicity study, chronic toxicity study, subchronic toxicity study
5.	Alkyldimethyl benzyl ammonium chloride	Teratology study
6.	Azoxystrobin	Teratology study

7.	Baquacil	Teratology study
8.	BAS510F	Oncogenicity study
9.	Bellacide	Low NOEL
10.	Bensulide	Chronic toxicity study, low NOEL, delayed neurotoxicity study
11.	Bentazon	Teratology study, oncogenicity study
12.	Bifenazate	Chronic toxicity study, combined toxicity study
13.	Boric acid	Chronic toxicity study, teratology study
14.	Bromacil	Oncogenicity study, genotoxicity study
15.	Buprofezin	Subchronic toxicity study, chronic toxicity study, combined toxicity study, teratology study
16.	Cacodylic acid	Genotoxicity study, chronic toxicity study, oncogenicity study, teratology study
17.	Carboxin	Genotoxicity study, oncogenicity study, chronic toxicity study
18.	Clomazone	Chronic toxicity study, teratology study
19.	Chlorflurenol	Chronic toxicity study, teratology study
20.	Chlorthal-dimethyl	Combined oncogenicity/chronic toxicity study, oncogenicity study
21.	Clothianidin	Genotoxicity, neurotoxicity (subchronic study)
22.	Cryolite	Oncogenicity study
23.	Cyanurate monosodium	Combined oncogenicity/chronic toxicity study
24.	Cyclanilide	Combined oncogenicity/chronic toxicity study

25.	Cymoxanil	Genotoxicity study, chronic toxicity study, teratology study
26.	Cypermethrin	Chronic toxicity studies, oncogenicity study, reproduction study
27.	Cyphenothrin	Neurotoxicity
28.	Cyprodinil	Subchronic toxicity study, combined oncogenicity/chronic toxicity study
29.	Dichloran/Dicloran	Genotoxicity study, chronic toxicity study, reproduction study
30.	Didecylmethyl-ammonium chloride	Low NOEL
31.	Difenoconazole	Teratology studies, combined oncogenicity/chronic toxicity study
32.	Difethialone	Low NOEL (acute, subchronic)
33.	Dimethomorph	Oncogenicity study, chronic toxicity study, genotoxicity study
34.	Dinotefuran	Reproduction study, chronic toxicity study, subchronic toxicity study
35.	Diphenylamine	Combined chronic toxicity/oncogenicity study
36.	Dipropyl iso-cinchomeronate (MGK-326)	Oncogenicity studies
37.	Dithiopyr	Subchronic toxicity studies
38.	Diuron	Genotoxicity study, oncogenicity studies
39.	Dodine	Oncogenicity study
40.	2,4-DB (4-(2,4-dichloro-phenoxy)butyric acid)	Genotoxicity studies, reproduction study
41.	Endothall	Chronic toxicity study, oncogenicity study

42.	Esbiothrin	Genotoxicity study, reproduction study
43.	Ethalfluralin	Chronic toxicity study, genotoxicity study, combined oncogenicity/chronic toxicity study
44.	Ethofumesate	Teratology study
45.	ETOC	Subchronic toxicity study, chronic toxicity study, teratology study
46.	Etoxazole	Genotoxicity study
47.	Fenarimol	Combined oncogenicity/chronic toxicity study
48.	Fludioxonil	Combined oncogenicity/chronic toxicity study, subchronic toxicity study
49.	Fluroxypyr	Chronic toxicity study, subchronic toxicity study
50.	Flurprimidol	Chronic toxicity study, teratology study, reproduction study
51.	Fluvalinate	Genotoxicity study, reproduction study, teratology study, chronic toxicity study
52.	Forchlorfenuron	Genotoxicity study
53.	Formaldehyde	Genotoxicity study, oncogenicity study
54.	Glyphosate-trimesium	Teratology study, reproduction study
55.	Halosulfuron	Chronic toxicity study
56.	Hexahydro-1,3,5-triethyl-S-triazine	Teratology study
57.	Hexythiazox	Oncogenicity study
58.	Imidacloprid	Combined oncogenicity/chronic toxicity study, teratology study, genotoxicity study
59.	Imiprothrin	Teratology study, neurotoxicity study, chronic toxicity study, genotoxicity study

60.	Isoxaben	Oncogenicity studies, genotoxicity study
61.	Kresoxim-methyl	Combined chronic toxicity/oncogenicity study
62.	*Lindane*	Oncogenicity, reproductive toxicity
63.	MCPA	Genotoxicity study
64.	Mecoprop (MCPP)	Oncogenicity study, genotoxicity study
65.	Mefenoxam	Genotoxicity study
66.	Mefluidide	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study
67.	Metalaxyl	Genotoxicity study
68.	Methomyl	Oncogenicity study, chronic toxicity study
69.	Methoxyfenozide	Chronic toxicity study, combined toxicity study, reproduction study
70.	Metribuzin	Chronic toxicity study
71.	MSMA/MAA	Combined oncogenicity/chronic toxicity study
72.	Napropamide	Combined oncogenicity/chronic toxicity study, genotoxicity study
73.	Napthalene acetic acid	Reproduction study, teratology study, chronic toxicity study, combined toxicity study
74.	Norflurazon	Chronic toxicity study
75.	O-benzyl-p-chlorophenol	Teratology study
76.	Oryzalin	Oncogenicity study, chronic toxicity study
77.	Oxyfluorfen	Genotoxicity study, oncogenicity study, teratology study

78.	Oxythioquinox	Chronic toxicity study, reproduction study, teratology study, genotoxicity study
79.	Pebulate	Combined oncogenicity/chronic toxicity study, chronic toxicity study
80.	*Penoxsulam**	Oncogenicity
81.	Permethrin	Reproduction study, chronic toxicity study, oncogenicity study
82.	Phenol	Oncogenicity studies
83.	Phenothrin	Oncogenicity study, reproduction toxicity study
84.	Phorate	Low NOEL
85.	*Picaridin (KBR 3023)**	Subchronic toxicity, genotoxicity
86.	Picloram	Combined chronic toxicity/oncogenicity study
87.	Prometon	Low NOEL
88.	Propamocarb HCL	Chronic toxicity study, teratology study
89.	Propiconazole	Low NOEL, chronic toxicity study
90.	PT807-HCL	Subchronic toxicity study, chronic toxicity studies
91.	Pymetrozine	Combined oncogenicity/chronic toxicity study, oncogenicity study, acute neurotoxicity study
92.	Pyraflufen-ethyl	Chronic toxicity study, oncogenicity study, genotoxicity study
91.	Pyrethrins	Reproduction study, genotoxicity study, oncogenicity study
92.	Pyridaben	Low NOEL
93.	Pyridate	Chronic toxicity study

94.	*Pyrimethanil**	Oncogenicity
95.	Pyriproxyfen	Chronic toxicity study
96.	Pyrithiobac-Na	Combined chronic toxicity/oncogenicity study
97.	Quinclorac	Chronic toxicity study; genotoxicity study
98.	Resmethrin	Teratology study, oncogenicity study, chronic toxicity study, reproduction study
99.	Rimsulfuron	Chronic toxicity studies
100.	Simazine	Combined oncogenicity/chronic toxicity study
101.	Spinosad	Chronic toxicity study, combined chronic toxicity/oncogenicity study
102.	*Sulfosulfuron**	Chronic toxicity, oncogenicity
103.	Sumithion	Low NOEL (subchronic study), oncogenicity study, reproduction study
104.	TCMTB	Oncogenicity study
105.	Tebufenozide	Chronic toxicity studies
106.	Tetrachlorvinphos	Oncogenicity study, genotoxicity study
107.	Tetrakis	Teratology study
108.	Thiamethoxan	Combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study
109.	Thiodicarb	Oncogenicity study, reproduction study, genotoxicity study
110.	Thiram	Low NOEL, teratology study, chronic toxicity study, combined oncogenicity/chronic toxicity study
111.	Trichlorfon	Combined chronic toxicity/oncogenicity study, genotoxicity study

112	Triclopyr	Genotoxicity study, low NOEL
113.	Trifloxystrobin	Oncogenicity study, chronic toxicity study, genotoxicity study
114.	Triflumizole	Chronic toxicity study
115.	Trifluralin	Combined oncogenicity/chronic toxicity study, oncogenicity study
116.	Triforine	Teratology study, oncogenicity study
117.	Tris (hydroxymethyl nitromethane*)*	Genotoxicity study, teratology study
118.	Trisulfuron-methyl	Chronic toxicity study, oncogenicity study
119.	Uniconazole-P	Chronic toxicity study, oncogenicity study, genotoxicity study, low NOEL
120.	XDE-007	Reproduction study
121.	Zinc omadine	Teratology studies

Low Priority

1.	Alachlor	Oncogenicity study, chronic toxicity study, low NOEL
2.	Anilazine	Genotoxicity study
3.	Azadirachten	None identified
4.	Bacillus subtilis	None identified
5.	Bacillus thuringiensis	None identified
6.	Beauveria bassiana	None identified
7.	Benefin	Combined chronic toxicity/oncogenicity study

8.	Benzyl benzoate	None identified
9.	Bioban	Teratology study
10.	Blue Circle (Pseudomonas)	None identified
11.	Bronopol	Chronic toxicity study, low NOEL
12.	Butylate	Genotoxicity study, neurotoxicity study
13.	*N-Butyl-1,2-benzisothiazole-3-one*	Genotoxicity
14.	Candida olephila	None identified
15.	Carfentrazone-ethyl	Chronic toxicity studies
16.	1-(3-Chloroallyl)-3,5,7-triaza-azoniaadamantane	Genotoxicity study, teratology study
17.	4-chloro-3,5-xylenol	Genotoxicity study
18.	Chlorhexidine diacetate	Dermal (local) effects
19.	Chlorpropham	Genotoxicity study
20.	Chlorsulfuron	Chronic toxicity study
21.	Cimectacarb	Combined oncogenicity/chronic toxicity study
22.	Clethodim	Genotoxicity study
23.	Clopyralid	Subchronic toxicity study; combined oncogenicity/chronic toxicity study
24.	2,4-DP	Combined oncogenicity/chronic toxicity study
25.	1,2-Dibromo-2,4-dicyanobutane (Tektamer 38)	Subchronic toxicity study
26.	4,5-Dichloro-2-noctyl-3(2H)-isothiazolone (Sea-Nine)	Antimicrobial; local corrosive effects

27.	Desmediphan	Genotoxicity study, teratology study
28.	Dichlorprop-p	Chronic toxicity studies
29.	Difenzoquat methyl sulfate	Chronic toxicity study
30.	Diflufenzopyr	Teratology study, reproduction study
31.	Dimethipin	Chronic toxicity study
32.	Dimethoxane	Oncogenicity study, genotoxicity study
33.	DTEA	None identified
34.	5,5-dimethylhydantoin	Chronic toxicity studies
35.	4,4-dimethyloxazolidine	Genotoxicity study
36.	Ethephon	Genotoxicity study
37.	Fenamidone	Chronic toxicity studies, genotoxicity studies
38.	Fenhexamid	Subchronic and chronic toxicity studies
39.	Fluridone	Chronic toxicity study, oncogenicity study
40.	Flutolonil	Genotoxicity study, combined oncogenicity/ chronic toxicity study
41.	Foramsulfuron	Genotoxicity study
42.	Formetanate	Genotoxicity study
43.	Fosetyl-AL	Combined oncogenicity/chronic toxicity study
44.	Frostban A&B (Pseudomonas)	None identified
45.	Gliocladium verens	None identified
46.	Glyphosate	Oncogenicity studies

47.	Halofenozide	Teratology study, subchronic toxicity study
48.	Hexazinone	Genotoxicity study
49.	Hydropene	Chronic toxicity study, oncogenicity study
50.	5-hydroxymethyl-1-aza-3,7-dioxabicyclo-(3,3,0)octane	Genotoxicity study
51.	Imazamethabenz-methyl	Subchronic toxicity study, combine chronic toxicity/oncogenicity study
52.	Imazamox	Teratology studies
53.	*Imazapic**	Chronic toxicity study
54.	Imazapyr	Teratology study
55.	Imazethapyr	Genotoxicity study, teratology study
56.	Intercept	Teratology study
57.	Irgarol	None identified
58.	Lithium (perfluoro octane) sulfonate	Low NOELs in developmental and subchronic toxicity studies
59.	Maleic hydrazide	Genotoxicity study
60.	Maneb (also see ETU-High Priority)	Genotoxicity study
61.	Mepiquat chloride	Chronic toxicity studies
62.	Mesosulfuron-methyl	Subchronic toxicity study
63.	Metaldehyde	Chronic toxicity study
64.	Methylene bisthiocyanate	Genotoxicity study
65.	Metolachlor	Oncogenicity study, chronic toxicity study
66.	Mycostop (Streptomyces)	None identified
67.	Nicosulfuron (Accent)	None identified

68.	Nithiazine	Neurotoxicity study
69.	Nitrapyrin	Combined oncogenicity/chronic toxicity study
70.	4-(2-nitrobutyl) morpholine/ 4,4'-(2-ethyl-2-nitrotrimethylene) morpholine	Genotoxicity study
71.	Octhilinone	Genotoxicity study
72.	Oxamyl	Chronic toxicity study
73.	Parachlorometacresol	Antimicrobial; local irritant
74.	Pendimethalin	Oncogenicity study
75.	Phenmedipham	None identified; incomplete data base
76.	Piperonyl butoxide	Oncogenicity study
77.	Poly(oxy-1,2-ethanediyl), -isooctadecyl - hydroxyl	None identified
78.	Prodiamine	Teratology study, genotoxicity study
79.	Prohexadione	Chronic toxicity study, genotoxicity study
80.	Prometryn	None identified
81.	Promexal	Subchronic toxicity study, teratology study
82.	*Propoxycarbazone-sodium**	None identified
83.	Pseudomonas syringea	None identified
84.	P-tert-amylphenol	None identified
85.	Pyrazon	Chronic toxicity studies
86.	Rotenone	Genotoxicity study
87.	Sethoxydim	Teratology study, chronic toxicity study

88.	Siduron	Oncogenicity study
89.	Sodium hydroxymethyl glycinate	None identified
90.	Tebuthiuron	Reproduction study, teratology study, mutagenicity study
91.	Tetramethrin	Reproduction study, oncogenicity study, teratology study
92.	Thiobencarb	Genotoxicity study

DATA-EXEMPT ACTIVE INGREDIENTS*

Under SB-950

High Priority	Moderate Priority	Low Priority
Aluminum/Magnesium Phosphide	Copper hydroxide	Ammonium Tall Oil (fatty acid soap)
	Sulfur	Carbon dioxide
	Sulfur dioxide	Chlorine
		Ethyl alcohol
		Fatty acids (methyl esters)
		Hydrogen chloride
		Isopropyl alcohol
		Metallic silver
		Phosphoric acid
		Sodium hydroxide
		Streptomycin
		Warfarin
		Zinc oxide/chloride

*Active ingredients for which no additional toxicology data were required under SB 950.

CHANGES TO THE RISK ASSESSMENT PRIORITIZATION LIST

A. Changes in Status of Active Ingredients Already on Prioritization List

None

B. Active Ingredients Removed from Prioritization List (1)[a]

Sulfuryl fluoride

C. Active Ingredients Added to Prioritization List (12)

.

N-Butyl-1,2-benziothiazole-3-one (Low Priority) Not previously on list

Flonicamid (High Priority) New active ingredient

Imazapic (Low Priority) New active ingredient

Novaluron (High Priority) New active ingredient

Penoxsulam (Moderate Priority) New active ingredient

Picaridin (Moderate Priority) New active ingredient

Propoxycarbazone-sodium (Low Priority) New active ingredient

Pyrimethanil (Moderate Priority) New active ingredient

Sodium tetrathiocarbonate (High Priority) Not previously on list

Spiromesifin (High Priority) New active ingredient

Sulfosulfuron (Moderate Priority) New active ingredient

Thiacloprid (High Priority) New active ingredient

---

a/ A completed risk assessment must be approved by Assistant Director before it can be removed from the PREC prioritization list

STATUS OF ACTIVE INGREDIENTS CURRENTLY IN RISK ASSESSMENT

Note: The following list only includes those active ingredients that are currently in risk assessment. It does not include the active ingredients in risk mitigation/risk management. Once the risk assessment for a specific active ingredient has been completed and approved by the Assistant Director, that active ingredient is removed from the SB-950/PREC Prioritization List. In addition to conducting a risk assessment under SB-950 for occupational and residential exposures, many risk assessments contain a dietary component under AB-2161 and an air component under AB-1807. Whenever possible, these components are included in one, comprehensive risk characterization document.

The following stages of the risk assessment process are included in this status section:

Hazard Identification Stage: includes the development of the Toxicology Profile Section and the selection of the definitive studies, critical endpoints and NOEL/LOEL/oncogenicity potency values that will be used for risk characterization. Responsibility: Medical Toxicology Branch.

Exposure Assessment Stage: includes the development of occupational, residential, dietary (food/water), ambient air and off-site air exposure scenarios. Responsibility: Worker Health and Safety Branch for occupational, residential and air. Medical Toxicology Branch for dietary.

Risk Characterization Stage: includes the development of quantitative values used to assess the risk from critical NOELs/oncogenic potency factors and exposure values. Responsibility: Medical Toxicology Branch

Review Stage: includes the review of the final draft of the Risk Characterization Document within DRP and externally by OEHHA, US EPA and other interested parties. Also includes development of DPR response to reviewers comments.

Approval Stage: completed Risk Characterization Document awaiting approval by Assistant Director.

Inactive : No current risk assessment activities because of higher priorities.

Active Ingredients

1. Acephate - Hazard identification and exposure assessment stages

2. Carbaryl – Hazard identification and exposure stages

3. Carbofuran – Review stage (occupational, dietary, air)

4. Chloropicrin – Hazard identification and exposure assessment stages

STATUS OF ACTIVE INGREDIENTS CURRENTLY IN RISK ASSESSMENT (CONTINUED)

5. Chlorothalonil- Approval stage (dietary)
6. Chlorpyrifos - Review stage (occupational/air)
7. Cyfluthrin – Hazard identification phase
8. 1, 3 dichloropropene (Telone) – Risk characterization phase (air)
9. ETU - Hazard identification stage (dietary)
10. Endosulfan – Exposure assessment stage (occupational, dietary, air)
11. Fipronil- Hazard identification stage
12. Imidacloprid – Review stage (dietary)
13. Indoxacarb– Hazard identification and exposure assessment stages
14. Mancozeb-- Hazard identification stage (dietary)
15. Maneb - Hazard identification stage (dietary)
16. Methamidophos – Approval stage (occupational/dietary)
17. Methidathion (addendum) – Approval stage (air)
18. Methyl iodide- Hazard identification and exposure assessment stages
19. Methyl parathion - RCD completed/approved (dietary)
20. Methyl parathion – Exposure assessment stage (occupational)
21. Orthophenylphenol – Review stage (dietary)
22. Paraquat-- Hazard identification stage
23. Propargite – Approval stage (dietary)
24. Propargite-Exposure assessment stage (occupational)

25. Propyzamide - Inactive

26. Simazine-Hazard identification and exposure assessment stages

27. *Sodium tetrathiocarbonate - Hazard identification and exposure assessment stages*

28. Sulfuryl fluoride – Approval stage (occupational/air)